Media / Science Center
Media/
Science Center
Videos
Pain Week 2023
Dr. Dart introducing MPAR overdose protection
Podcasts
22:34
Drug Discovery World – Dr Lynn Kirkpatrick explains PF614-MPAR
12:12
Stock Day Podcast – Dr. Lynn Kirkpatrick talks about TAAP, MPAR and pain relief products
Abstracts & Manuscripts
Clinical evaluation of PF614, a novel TAAP prodrug of oxycodone, versus OxyContin in a multi-ascending dose study with a bioequivalence arm in healthy volunteers.
Download PDF
A Novel Trypsin Activated Abuse Protected (TAAP™) ER Oxycodone Prodrug with Overdose Protection
Download PDF
Preventing Prescription Drug Overdoses, Clinical development of Trypsin-Activated Abuse Deterrent (TAAP) Opioids with Overdose Protection
Download PDF
Development of an extended release nafamostat formulation for prescription drug overdose protection.
Download PDF
PF614-MPAR: A Novel Trypsin Activated Abuse Protected (TAAP™) Extended-Release Oxycodone Prodrug with Overdose Protection. In: Symposium on Severe Pain, Next Generation Solutions – PF614 / PF614-MPAR.
Download PDF
PF614-MPAR: A Novel Trypsin Activated Abuse Protected (TAAP™) Extended-Release Oxycodone Prodrug with Overdose Protection.
Download PDF
PF614-MPAR: A Novel Trypsin Activated Abuse Protected (TAAP™) Extended-Release Oxycodone Prodrug with Overdose Protection.
Download PDF
Intranasal and Oral Human Abuse Potential (HAP) Studies with PF614: A Novel Trypsin Activated Abuse Protected (TAAP) Oxycodone Prodrug.
Download PDF
Intranasal and Oral Human Abuse Potential (HAP) Studies with PF614: A Novel Trypsin Activated Abuse Protected (TAAP) Extended-Release Oxycodone Prodrug.
Download PDF
Development of a Multi-Pill Abuse Resistant Extended-Release Formulation to Prevent Opioid Overdose.
Download PDF
Intranasal Human Abuse Potential of PF614: A Novel ‘Next Generation’ Trypsin Activated Abuse Protected (TAAP) Opioid.
Download PDF
MPAR: A Chemical Approach to Opioid Overdose Protection.
Download PDF
The Next Generation Opioid Products for Moderate-Severe Pain
Download PDF
Nonclinical Safety Assessment of PF614, a Novel TAAP Prodrug of Oxycodone
Download PDF
First-in-human pharmacokinetics & safety study of PF614: orally activated oxycodone prodrug.
Download PDF
First-in-human pharmacokinetics & safety study of PF614, orally activated oxycodone prodrug
Download PDF
In vitro and in vivo assessment of the abuse potential of PF614, a novel BIO-MD™ prodrug of oxycodone
Download PDF
First in man evaluation of PF329
Download PDF